NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:NOV • DK0062498333
42.31 EUR
+0.94 (+2.27%)
Last: Feb 10, 2026, 10:45 AM
NOV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. NOV scores excellent on profitability, but there are concerns on its financial health. NOV has a correct valuation and a medium growth rate. NOV also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- In the past year NOV was profitable.
- NOV had a positive operating cash flow in the past year.
- Each year in the past 5 years NOV has been profitable.
- NOV had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- NOV has a better Return On Assets (18.87%) than 98.18% of its industry peers.
- NOV's Return On Equity of 52.79% is amongst the best of the industry. NOV outperforms 94.55% of its industry peers.
- NOV has a better Return On Invested Capital (30.79%) than 98.18% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.21%.
- The 3 year average ROIC (43.61%) for NOV is well above the current ROIC(30.79%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROIC | 30.79% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
1.3 Margins
- The Profit Margin of NOV (33.14%) is better than 100.00% of its industry peers.
- NOV's Profit Margin has been stable in the last couple of years.
- NOV has a better Operating Margin (41.30%) than 94.55% of its industry peers.
- NOV's Operating Margin has been stable in the last couple of years.
- NOV has a Gross Margin of 80.98%. This is amongst the best in the industry. NOV outperforms 83.64% of its industry peers.
- NOV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% |
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
- The number of shares outstanding for NOV remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, NOV has more shares outstanding
- NOV has a worse debt/assets ratio than last year.
2.2 Solvency
- NOV has an Altman-Z score of 4.11. This indicates that NOV is financially healthy and has little risk of bankruptcy at the moment.
- NOV has a Altman-Z score (4.11) which is comparable to the rest of the industry.
- NOV has a debt to FCF ratio of 4.52. This is a neutral value as NOV would need 4.52 years to pay back of all of its debts.
- NOV has a Debt to FCF ratio (4.52) which is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
- NOV's Debt to Equity ratio of 0.61 is in line compared to the rest of the industry. NOV outperforms 52.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 4.11 |
ROIC/WACC4.58
WACC6.72%
2.3 Liquidity
- NOV has a Current Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- NOV has a Current ratio of 0.80. This is amonst the worse of the industry: NOV underperforms 87.27% of its industry peers.
- NOV has a Quick Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of NOV (0.57) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 3.01% over the past year.
- NOV shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.95% yearly.
- NOV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
- NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%
3.2 Future
- Based on estimates for the next years, NOV will show a small growth in Earnings Per Share. The EPS will grow by 6.65% on average per year.
- Based on estimates for the next years, NOV will show a small growth in Revenue. The Revenue will grow by 5.90% on average per year.
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 13.56 indicates a correct valuation of NOV.
- 74.55% of the companies in the same industry are more expensive than NOV, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 28.06. NOV is valued rather cheaply when compared to this.
- NOV is valuated correctly with a Price/Forward Earnings ratio of 13.87.
- Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than 76.36% of the companies in the same industry.
- NOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 13.87 |
4.2 Price Multiples
- NOV's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NOV is cheaper than 76.36% of the companies in the same industry.
- NOV's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. NOV is more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.44 | ||
| EV/EBITDA | 9.87 |
4.3 Compensation for Growth
- NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.65
EPS Next 2Y1.88%
EPS Next 3Y6.76%
5. Dividend
5.1 Amount
- NOV has a Yearly Dividend Yield of 4.17%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.94, NOV pays a better dividend. On top of this NOV pays more dividend than 83.64% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.80, NOV pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
5.2 History
- On average, the dividend of NOV grows each year by 19.05%, which is quite nice.
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of NOV is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
FRA:NOV (2/10/2026, 10:45:48 AM)
42.31
+0.94 (+2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)05-05 2026-05-05
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap188.00B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts71.88
Price Target54.04 (27.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.64%
Min EPS beat(2)-7.04%
Max EPS beat(2)5.77%
EPS beat(4)2
Avg EPS beat(4)0.38%
Min EPS beat(4)-7.04%
Max EPS beat(4)5.77%
EPS beat(8)5
Avg EPS beat(8)1.56%
EPS beat(12)8
Avg EPS beat(12)1.83%
EPS beat(16)11
Avg EPS beat(16)1.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.88%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.33%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.44%
Revenue beat(8)2
Avg Revenue beat(8)-0.05%
Revenue beat(12)5
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)0.73%
PT rev (1m)-1.65%
PT rev (3m)-11.79%
EPS NQ rev (1m)-5.7%
EPS NQ rev (3m)-11.39%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-11.16%
Revenue NQ rev (1m)-21.29%
Revenue NQ rev (3m)49.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 13.87 | ||
| P/S | 4.54 | ||
| P/FCF | 48.44 | ||
| P/OCF | 11.79 | ||
| P/B | 7.24 | ||
| P/tB | 21.94 | ||
| EV/EBITDA | 9.87 |
EPS(TTM)3.12
EY7.37%
EPS(NY)3.05
Fwd EY7.21%
FCF(TTM)0.87
FCFY2.06%
OCF(TTM)3.59
OCFY8.48%
SpS9.31
BVpS5.85
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.65
Graham Number20.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROCE | 39.01% | ||
| ROIC | 30.79% | ||
| ROICexc | 33.56% | ||
| ROICexgc | 59.2% | ||
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% | ||
| FCFM | 9.38% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 0.79 | ||
| Cap/Depr | 409.94% | ||
| Cap/Sales | 29.16% | ||
| Interest Coverage | 37.34 | ||
| Cash Conversion | 79.59% | ||
| Profit Quality | 28.3% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 4.11 |
F-Score5
WACC6.72%
ROIC/WACC4.58
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year13.84%
EBIT Next 3Y11.7%
EBIT Next 5Y9.7%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%
NOVO NORDISK A/S-B / NOV.DE FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
What is the profitability of NOV stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for NOV stock?
The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -2.28% in the next year.
Is the dividend of NOVO NORDISK A/S-B sustainable?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.